In this large, multicenter, propensity-matched, retrospective study, patients with ischemic stroke who received tPA and had received DOACs within two days of thrombolytics were found to have significantly lower risk of death, ICH, and bleeding when compared to patients who received tPA without prior DOACs. The gene discussed is PLAT; the disease is ischemic stroke.